
Mazdutide
Research Peptide | Lyophilized Powder | Batch Tested
For laboratory research use only. Not for human or animal consumption. Insulated shipping · Styrofoam box available.
Product Overview
Mazdutide is an investigational dual GLP-1 and glucagon receptor agonist peptide studied in metabolic and energy-balance research. By combining GLP-1-driven satiety with glucagon-driven energy expenditure in a single molecule, it is used to explore a different receptor balance than GIP/GLP-1 agonists.
| Test | Result | Status |
|---|---|---|
| Purity | 98.8% | Passed ✓ |
| Test | Result | Status |
|---|---|---|
| Purity | 99.3% | Passed ✓ |
Research Information
Mazdutide is used to examine how simultaneous GLP-1 and glucagon receptor activation influences energy expenditure, appetite, glucose control and hepatic lipid metabolism in preclinical models. Research contrasts glucagon-associated thermogenesis with GLP-1-associated satiety, helping to characterize the trade-offs of dual agonism in metabolic tool compounds. Supplied strictly for in-vitro and laboratory research use only — not for human or animal consumption.
Mazdutide Research & Studies
What is Mazdutide?
Mazdutide is an investigational synthetic peptide designed as a dual agonist of the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR). In laboratory settings it is examined as a single-molecule tool that combines GLP-1 receptor engagement with glucagon receptor engagement. Researchers use it to probe how concurrent activation of these two receptors shapes energy-balance and metabolic signaling pathways in controlled model systems. It is supplied exclusively for in-vitro and laboratory research use.
Mechanism of Action
Mazdutide binds and activates both GLP-1R and GCGR, producing overlapping yet distinct intracellular cascades. GLP-1R stimulation is studied for its effects on satiety-related signaling and glucose-dependent pathways, while GCGR stimulation is examined for its influence on hepatic energy expenditure and lipid-handling routes. The dual-receptor profile allows investigators to compare the relative contribution of each receptor to overall metabolic readouts in cell-based and tissue assays. This balanced agonism differs from pure GLP-1 or GIP/GLP-1 co-agonist tools.
Primary Areas of Research
Laboratory work with Mazdutide centers on energy expenditure, appetite-related signaling, glucose homeostasis, and hepatic lipid metabolism. Preclinical model systems are used to dissect how simultaneous GLP-1R and GCGR activation alters thermogenic and satiety pathways. Comparative studies place Mazdutide alongside other dual or mono-agonists to map receptor-balance trade-offs. These investigations remain confined to in-vitro assays and non-clinical experimental platforms.
Key Research Findings
Published preclinical characterizations indicate that dual GLP-1R/GCGR engagement can modulate markers of energy expenditure and lipid flux in hepatic and adipose cell models. Observations also include shifts in glucose-handling pathways that differ from those produced by selective GLP-1 agonists alone. Such data help define the pharmacologic signature of glucagon-associated thermogenesis versus GLP-1-associated satiety signals. All reported outcomes derive from controlled laboratory systems and do not extend beyond research contexts.
Research Handling & Considerations
Mazdutide is provided as a research-grade peptide intended solely for in-vitro and laboratory experimentation. Standard peptide-handling practices—including appropriate reconstitution solvents, storage temperature, and avoidance of repeated freeze-thaw cycles—are recommended to preserve structural integrity. Investigators should confirm receptor selectivity and assay conditions when designing dual-agonist experiments. The compound is not intended for human or animal consumption or any form of administration outside controlled research settings.
Frequently Asked Questions
Mazdutide is studied as a dual agonist that activates both the GLP-1 receptor and the glucagon receptor, allowing examination of concurrent signaling through these two pathways.
Explore Other High-Purity Peptides

Semaglutide

Tirzepatide

Retatrutide
